{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:42:09Z","timestamp":1793954529742,"version":"4.8.0"},"reference-count":30,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Malignancies reported in children using tumor necrosis factor \u03b1 (TNF\u03b1) blockers have raised concerns of a potential increased risk. This study was undertaken to investigate postmarketing reports of malignancy in children treated with TNF blockers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The FDA's Adverse Event Reporting System was searched to identify malignancies associated with the use of infliximab, etanercept, and adalimumab in children in whom therapy was initiated between the ages of 0 and 18 years. The reporting rates for infliximab and etanercept were compared with the background rate of malignancy in the general pediatric population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty\u2010eight reports of malignancy in children were identified: 31 following infliximab use, 15 following etanercept use, and 2 following adalimumab use. Half of the malignancies reported were lymphomas and included both Hodgkin's and non\u2010Hodgkin's lymphoma. The remaining reported cases involved a variety of different malignancies including leukemia, melanoma, and solid organ cancers. The majority of the reported cases (88%) involved the concomitant use of other immunosuppressants. Reporting rates for malignancy showed that infliximab had a consistently higher reporting rate when compared with background rates in the general pediatric population for lymphomas and all malignancies. The reporting rates for etanercept were elevated above background for lymphomas and were on par with background for all malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>There is evidence that treatment with TNF blockers in children may increase the risk of malignancy. However, the cases were confounded by the potential risk of malignancy associated with underlying illnesses and the use of concomitant immunosuppressants; therefore, a clear causal relationship could not be established.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.27511","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T18:42:13Z","timestamp":1271184133000},"page":"2517-2524","source":"Crossref","is-referenced-by-count":221,"title":["Tumor necrosis factor \u03b1 blockers and malignancy in children: Forty\u2010eight cases reported to the food and drug administration"],"prefix":"10.1002","volume":"62","author":[{"given":"Peter","family":"Diak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"La Grenade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Lemery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,3]]},"reference":[{"key":"e_1_2_6_2_2","unstructured":"Food and Drug Administration. Early communication about an ongoing safety review of Tumor Necrosis Factor (TNF) blockers (marketed as Remicade Enbrel Humira and Cimzia). URL:www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070725.htm."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00237-9"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199710093371502"},{"key":"e_1_2_6_6_2","unstructured":"Food and Drug Administration. Drugs@FDA. Infliximab etanercept and adalimumab label information. URL:www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-995OC"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21869"},{"key":"e_1_2_6_9_2","first-page":"S91","article-title":"Malignancy in juvenile idiopathic arthritis","volume":"60","author":"Bernatsky S","year":"2009","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.sempedsurg.2007.04.010"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z"},{"key":"e_1_2_6_12_2","unstructured":"Food and Drug Administration. Adverse Event Reporting System (AERS). URL:www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm."},{"key":"e_1_2_6_13_2","unstructured":"Drug utilization sources: Remicade \u2010 Centocor Ortho Biotech Inc. data on file; Enbrel \u2010 Amgen Inc.; Humira \u2010 IMS Health NPA Plus 2006\u20102007. Information derived by Abbott from data provided by Wolters Kluwer Health Source Lx 2006\u20102007."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/86297"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2007.00566.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.03.027"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10679"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31802f6424"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e3181957a11"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"Begaud B","year":"2002","journal-title":"JAMA"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.24.3081"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1535"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629050-00003"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.11.3909"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.bor.0000126149.96627.82"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2007.05.003"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199501053320103"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440230078037"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.2001.00022.x"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27511","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:51:56Z","timestamp":1698785516000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1002\/art.27511"],"URL":"https:\/\/doi.org\/10.1002\/art.27511","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}